Table 2 Clinical characteristics of participants receiving care at Debre Markos and Felege Hiwot referral hospitals, Ethiopia, 2018–2019 (n = 186)
Variables | Control group (n = 98) | Treatment group (n = 88) | p values |
|---|---|---|---|
Frequency (%) | Frequency (%) | ||
Comorbidity | |||
Yes | 17 (17.3%) | 32 (36.4%) | 0.000 |
No | 81 (82.7%) | 56 (63.6%) | |
Current medication | |||
Furosemide | 87 (88.8%) | 88 (100%)) | 0.000 |
Spironolactone | 76 (77.6%) | 83 (94.3%) | |
ACE | 42 (42.8%) | 55 (62.5%) | |
Aspirin | 44 (44.9%) | 12 (13.6%) | |
Lipid lowering drugs | 18 (18.3%) | 12 (13.6%) | |
Beta blockers | 51 (52%) | 44 (50%) | |
History of hospitalization | |||
Yes | 67 (68.4%) | 71 (80.7%) | 0.06 |
No | 31 (31.6%) | 17 (19.3%) | |
Chronic heart failure stage | |||
One | – | 5 (5.7%) | 0.000 |
Two | 3 (3.1%) | 14 (15.9%) | |
Three | 19 (19.4%) | 21 (23.9%) | |
Four | 76 (77.6%) | 48 (54.5%) | |